Background: The lesions of porokeratosis (PK) lead to skin atrophy and scarring as long as they spread centrifugally. PK affecting the nail unit is seldom described. Objective: The aim was to revise the previously reported cases of ungual PK and to present 3 new cases. Methods: A PubMed search was performed with the keywords “nail” and “porokeratosis.” Previously reported cases as well as 3 new cases are depicted in tables. Results: Only 11 cases of ungual PK were found; 3 new cases have been added. All patients presented with typical lesions of PK (Mibelli, isolated, segmental, or ostial eccrine types) that happened to affect nails due to nail matrix or nail bed compromise, resulting in mild to severe nail scarring, including irreversible anonychia. The present 3 case series contrast with the previous single case reports. Conclusions: PK affecting the nails is exceedingly rare. Changes in nails affected by PK are irreversible, since, as on the skin, this is a chronic scarring process.

  • Nail compromise in porokeratosis is rarely described.

  • Lesions in published cases include nail ridging, splitting, pterygium, and anonychia.

  • Nail dystrophy from porokeratosis results from the occurrence of a scarring process affecting the nail unit similar to the central area of the porokeratotic cutaneous lesion.

  • Porokeratotic nail compromise is progressively destructive and tends to cause permanent damage.

The term “porokeratosis” (PK) includes a group of nonrelated, inherited skin disorders that have in common the presence of a cornoid lamella on histopathology. The cornoid lamella consists of a parakeratotic column overlying a small vertical zone of dyskeratotic and vacuolated cells within the epidermis accompanying a focal loss of the granular layer [1]. The cornoid lamella represents the clinically visible raised margin of lesions of PK. More common types of PK include PK of Mibelli, disseminated superficial PK, segmental (linear) PK, eccrine ostial duct PK, and localized, nonsegmental PK (single lesion PK). Rarer forms have been described [1].

The classic clinical lesions of PK consist of slowing enlarging, isolated or confluent plaques with thin, raised, keratotic margins. As lesions grow centrifugally, the inner, central part of the lesion becomes thinned and atrophic. Here, we present 3 new patients with PK who besides their cutaneous lesions also presented PK affecting the nail unit, and review the previously published cases of ungual PK.

Ungual PK is very rarely described [2-12]. All previously reported cases of ungual PK are characterized by chronicity and tendency toward nail apparatus scarring with tendency to destruction of the nail plate.

Nail scarring occurs in clinical situations where the nail matrix or the nail bed is irreversibly damaged. Clinically, nail scaring ranges from mild (nail plate ridging) to intermediate (splitting), and severe (pterygium and anonychia). The commonest causes of nail scarring include lichen planus (LP) and severe trauma. Rarer causes include other scarring dermatoses such as discoid lupus erythematosus, graft versus host disease, mycosis fungoides, acquired epidermolysis bullosa, epidermolysis bullosa dystrophica, toxic epidermal necrolysis, dyskeratosis congenita, and, very rarely, PK.

A PubMed search (“nail + porokeratosis”) revealed only 11 reports of single patients. The features of these published cases are included on Table 1.

Table 1.

Published reports on ungual PK

Published reports on ungual PK
Published reports on ungual PK

Types of PK involved in these previously reported patients included single lesion PK (1 case), segmental (linear) PK (4), acral or more widespread PK of Mibelli (4), and eccrine ostial duct PK (1). Superficial forms of PK (actinic PK and disseminated superficial PK [1]) are not known to affect the nails. In all reported cases, an advancing cutaneous lesion of PF reached the nail unit, leading to progressive destruction of this structure. Clinical nail compromise included increasing forms of increased severity of nail scarring and destruction: ridging, longitudinal splitting, pterygium, and anonychia. In all patients, histopathological confirmation was obtained. In all cases, attempts to treatment completely failed.

This is the first published case series of ungual PK (Table 2). These 3 new patients presented typical nail scarring due to the poroketatotic process (Fig. 1). Patients 1 and 2 presented intermediate nail destruction characterized by ridging and splitting. They had typical PK of Mibelli, presenting lesions on the limbs that were not limited to the extremities (Fig. 1a, b). Patient 3 had a congenital, segmental lesion of PK that affected the inner right thigh, leg, and dorsum of the foot (Fig. 1c). Pterygium of the first and second toenails resulted from PK compromise of these areas. Histopathology of biopsied keratotic edges of lesions in the 3 patients confirmed the diagnosis of PK (Fig. 2). Longitudinal nail biopsies were not obtained, given the presence of many typical lesions elsewhere, where simple punch biopsies were more easily performed.

Table 2.

Case series of ungual PK

Case series of ungual PK
Case series of ungual PK
Fig. 1.

PK affecting the nails. Case 1: ridging and splitting. PK lesions with delicate keratotic edge and mildly atrophic center (arrows) (a). Case 2: splitting. Typical PK lesions are visible on the dorsum of the foot and surrounding the nail unit (b). Case 3: pterygium. Ungual lesions are located at the extremity of a segmental streak of linear PK (c). PK, porokeratosis.

Fig. 1.

PK affecting the nails. Case 1: ridging and splitting. PK lesions with delicate keratotic edge and mildly atrophic center (arrows) (a). Case 2: splitting. Typical PK lesions are visible on the dorsum of the foot and surrounding the nail unit (b). Case 3: pterygium. Ungual lesions are located at the extremity of a segmental streak of linear PK (c). PK, porokeratosis.

Close modal
Fig. 2.

PK: histopathology of a lesion of case 2. A parakeratotic cornoid lamella is seen emerging from the invaginated epidermis. H&E, ×100. PK, porokeratosis.

Fig. 2.

PK: histopathology of a lesion of case 2. A parakeratotic cornoid lamella is seen emerging from the invaginated epidermis. H&E, ×100. PK, porokeratosis.

Close modal

Squamous cell carcinomas (SCC) can arise at areas of chronic and intense scarring such as burns, morphea, discoid lupus erythematosus, LP, lupus vulgaris, epidermolysis bullosa dystrophica, hidradenitis, nonhealing ulcers, and, very rarely rarely, PK [13]. These diseases should not be considered “pre-malignant,” nonetheless SCC truly can arise in their chronic scars (Marjolin’s ulcer) [1, 13]. In theory, then, SCC can occur in a cicatricial anonychia due to PK. No such case has been reported so far, probably due to the extreme rarity of ungual PK. The occurrence of SCC in scars of ungual LP (a rare complication of a much more common entity) has been recently reviewed [13].

Nail compromise due to PK results from the occurrence of PK lesions in the vicinity. The centrifugal expansion of such lesions might affect the nail matrix and bed, resulting in scarring of these areas. Thus, albeit very rare in this location, PK will lead to irreversible nail changes.

All 3 patients have given written informed consent to publish photos and details of their cases. Research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. Written informed consent was obtained from all the patients involved, for publication of their case series and any accompanying images. Ethical approval was not obtained since this is a retrospective case series.

The authors have no conflicts of interest to declare.

The authors declare that there were no funding sources supporting this study.

T.M.Y.: patient management and writing of the manuscript; T.V.B.G.: writing of the manuscript and literature review, M.M.S.N.: idealization, patient management, and final review.

1.
Biswas
A
.
Cornoid lamellation revisited: apropos of porokeratosis with emphasis on unusual clinicopathological variants
.
Am J Dermatopathol
.
2015 Feb
;
37
(
2
):
145
55
. .
2.
Tseng
SS
,
Levit
EK
,
Ilarda
I
,
Garzon
MC
,
Grossman
ME
.
Linear porokeratosis with underlying bony abnormalities
.
Cutis
.
2002 Apr
;
69
(
4
):
309
12
.
3.
Chen
HH
,
Liao
YH
.
Onychodystrophy in congenital linear porokeratosis
.
Br J Dermatol
.
2002 Dec
;
147
(
6
):
1272
3
. .
4.
Karthikeyan
K
,
Thappa
DM
,
Udayashankar
C
.
Porokeratosis of mibelli with nail dystrophy
.
J Dermatol
.
2003 May
;
30
(
5
):
420
2
. .
5.
Dervis
E
,
Demirkesen
C
.
Generalized linear porokeratosis
.
Int J Dermatol
.
2006 Sep
;
45
(
9
):
1077
9
. .
6.
Kim
DS
,
Roh
MR
,
Lee
JH
,
Lee
KH
.
Pterygium unguis formation in porokeratosis of Mibelli
.
Br J Dermatol
.
2007 Jun
;
156
(
6
):
1384
5
. .
7.
Lee
P
,
Metz
B
,
O’Grady
T
,
Cunningham
B
.
Unilateral linear hyperkeratotic plaques
.
Pediatr Dermatol
.
2009 Jul–Aug
;
26
(
4
):
473
4
. .
8.
Garg
T
,
Ramchander
,
Varghese
B
,
Barara
M
,
Nangia
A
.
Generalized linear porokeratosis: a rare entity with excellent response to acitretin
.
Dermatol Online J
.
2011 May 15
;
17
(
5
):
3
.
9.
Robati
RM
,
Rahmati-Roodsari
M
,
Ayatollahi
A
,
Hejazi
S
.
Facial and bilateral acral porokeratosis with nail dystrophy: a case report
.
Dermatol Online J
.
2011 Jan 15
;
17
(
1
):
5
.
10.
Kohara
Y
,
Takeo
T
,
Oshima
Y
,
Akita
Y
,
Tamada
Y
,
Watanabe
D
.
Linear porokeratosis with nail dystrophy
.
Eur J Dermatol
.
2011 Jul–Aug
;
21
(
4
):
625
6
. .
11.
Pawar
M
.
Onychodystrophy due to porokeratosis of Mibelli: a rare association
.
Acta Dermatovenerol Alp Pannonica Adriat
.
2017 Jun
;
26
(
2
):
51
2
. .
12.
Rajesh
G
,
Devan
P
,
Keerthi
S
,
Karthikeyan
K
.
Acral porokeratosis associated with anonychia
.
Indian J Dermatol Venereol Leprol
.
2018 Jan-Feb
;
84
(
1
):
81
2
. .
13.
Takatu
CM
,
Gabbi
TVB
,
Nico
MMS
.
Squamous cell carcinoma arising in ungual lichen planus: report and review
.
Skin Appendage Disord
.
2021 Jan
;
7
(
1
):
54
7
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.